

FORM PTO-1390 (REV. 11-2000)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				0760-0298P
INTERNATIONAL APPLICATION NO.		INTERNATIONAL FILING DATE	U.S. APPLICATION NO. (if known, see 37 CFR 1.5)	
PCT/JP01/02936		April 5, 2001	09/980624	
TITLE OF INVENTION		ADSORBENT OF HIGH-MOBILITY-GROUP PROTEINS AND BODY FLUID-PURIFICATION COLUMN		
APPLICANT(S) FOR DO/EO/US		MARUYAMA, Ikuro; IDA, Nobuo; MASUKO, Sanae		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:				
<p>1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.</p> <p>2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.</p> <p>3. <input checked="" type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39 (1).</p> <p>4. <input type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (Article 31).</p> <p>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <ul style="list-style-type: none"> a. <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). b. <input checked="" type="checkbox"/> has been transmitted by the International Bureau. WO 01/74420 A1 c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). </p> <p>6. <input checked="" type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). <ul style="list-style-type: none"> a. <input checked="" type="checkbox"/> is transmitted herewith. b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4) </p> <p>7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)). <ul style="list-style-type: none"> a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> have been transmitted by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input checked="" type="checkbox"/> have not been made and will not be made. </p> <p>8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</p> <p>9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</p> <p>10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</p>				
Items 11. to 20. below concern document(s) or information included:				
<p>11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98, Form PTO-1449(s), and International Search Report (PCT/ISA/210) with 0 cited document(s).</p> <p>12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</p> <p>13. <input checked="" type="checkbox"/> A FIRST preliminary amendment.</p> <p>14. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.</p> <p>15. <input type="checkbox"/> A substitute specification.</p> <p>16. <input type="checkbox"/> A change of power of attorney and/or address letter.</p> <p>17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821-1.825.</p> <p>18. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4).</p> <p>19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).</p> <p>20. <input checked="" type="checkbox"/> Other items or information: <ul style="list-style-type: none"> 1.) Form (PCT/IB/308) 2.) Zero (0) Sheets of Formal Drawings </p>				

U.S. APPLICATION NO (if known, see 37 CFR 1.5)	INTERNATIONAL APPLICATION NO	ATTORNEY'S DOCKET NUMBER																																																				
09/980624	PCT/JP01/02936	0760-0298P																																																				
<p>21. <input checked="" type="checkbox"/> The following fees are submitted:</p> <p>BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO. \$1,040.00</p> <p>International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$890.00</p> <p>International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO. \$740.00</p> <p>International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$710.00</p> <p>International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4). \$100.00</p> <p>ENTER APPROPRIATE BASIC FEE AMOUNT =</p>		CALCULATIONS																																																				
<p>Surcharge of \$130.00 for furnishing the oath or declaration later than <input checked="" type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).</p> <table border="1"> <thead> <tr> <th>CLAIMS</th> <th>NUMBER FILED</th> <th>NUMBER EXTRA</th> <th>RATE</th> </tr> </thead> <tbody> <tr> <td>Total Claims</td> <td>48 - 20 =</td> <td>28</td> <td>X \$18.00</td> </tr> <tr> <td>Independent Claims</td> <td>2 - 3 =</td> <td>0</td> <td>X \$84.00</td> </tr> <tr> <td>MULTIPLE DEPENDENT CLAIM(S) (if applicable)</td> <td>Yes</td> <td></td> <td>+ \$280.00</td> </tr> <tr> <td colspan="4">TOTAL OF ABOVE CALCULATIONS = \$ 1,804.00</td> </tr> <tr> <td colspan="4"><input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.</td> </tr> <tr> <td colspan="4">SUBTOTAL = \$ 1,804.00</td> </tr> <tr> <td colspan="4">Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).</td> </tr> <tr> <td colspan="4">TOTAL NATIONAL FEE = \$ 1,804.00</td> </tr> <tr> <td colspan="4">Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +</td> </tr> <tr> <td colspan="4">TOTAL FEES ENCLOSED = \$ 1,804.00</td> </tr> <tr> <td colspan="2"></td> <td>Amount to be: refunded</td> <td>\$</td> </tr> <tr> <td colspan="2"></td> <td>charged</td> <td>\$</td> </tr> </tbody> </table>		CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	Total Claims	48 - 20 =	28	X \$18.00	Independent Claims	2 - 3 =	0	X \$84.00	MULTIPLE DEPENDENT CLAIM(S) (if applicable)	Yes		+ \$280.00	TOTAL OF ABOVE CALCULATIONS = \$ 1,804.00				<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				SUBTOTAL = \$ 1,804.00				Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				TOTAL NATIONAL FEE = \$ 1,804.00				Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +				TOTAL FEES ENCLOSED = \$ 1,804.00						Amount to be: refunded	\$			charged	\$	PTO USE ONLY
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE																																																			
Total Claims	48 - 20 =	28	X \$18.00																																																			
Independent Claims	2 - 3 =	0	X \$84.00																																																			
MULTIPLE DEPENDENT CLAIM(S) (if applicable)	Yes		+ \$280.00																																																			
TOTAL OF ABOVE CALCULATIONS = \$ 1,804.00																																																						
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.																																																						
SUBTOTAL = \$ 1,804.00																																																						
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).																																																						
TOTAL NATIONAL FEE = \$ 1,804.00																																																						
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +																																																						
TOTAL FEES ENCLOSED = \$ 1,804.00																																																						
		Amount to be: refunded	\$																																																			
		charged	\$																																																			
<p>a. <input checked="" type="checkbox"/> A check in the amount of <u>\$ 1,804.00</u> to cover the above fees is enclosed.</p> <p>b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed.</p> <p>c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>02-2448</u>.</p>																																																						
<p>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.</p>																																																						
<p>Send all correspondence to: Birch, Stewart, Kolasch & Birch, LLP or Customer No. 2292 P.O. Box 747 Falls Church, VA 22040-0747 (703) 205-8000</p>																																																						
<p>Date: <u>December 5, 2001</u></p>		<p>By <u>Gerald M. Murphy, Jr., #28,977</u> Gerald M. Murphy, Jr., #28,977</p>																																																				
<p>/rem</p>																																																						

09/9806:
JC13 Rec'd PCT/PTO 05 DEC

PATENT
0760-0298P

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: MARUYAMA, Ikuro et al.

Int'l. Appl. No.: PCT/JP01/002936

Appl. No.: New Group:

Filed: December 5, 2001 Examiner:

For: ADSORBENT OF HIGH-MOBILITY-GROUP
PROTEINS AND BODY FLUID-
PURIFICATION COLUMN

PRELIMINARY AMENDMENT

BOX PATENT APPLICATION

Assistant Commissioner for Patents
Washington, DC 20231

December 5, 2001

Sir:

The following Preliminary Amendments and Remarks are respectfully submitted in connection with the above-identified application.

AMENDMENTS

IN THE SPECIFICATION:

Please amend the specification as follows:

Before line 1, insert --This application is the national phase under 35 U.S.C. § 371 of PCT International Application No. PCT/JP01/02936 which has an International filing date of April 5, 2001, which designated the United States of America.--

IN THE CLAIMS:

Please amend the claims as follows:

18. (Amended) The adsorbent according to claim 1, wherein said water-insoluble carrier is in the form of beads.

19. (Amended) The adsorbent according to claim 1, which is used for therapy of sepsis.

20. (Amended) A body fluid-purification column for removing high-mobility-group proteins, comprising a column, and said adsorbent according to claim 1, which adsorbent is packed in said column.

23. (Amended) A method for adsorbing high-mobility-group proteins in body fluid, comprising contacting said adsorbent according to claim 1 with body fluid so as to adsorb said high-mobility-group proteins in said body fluid to said adsorbent.

25. (Amended) The method according to claim 23, wherein said body fluid is blood.

28. (Amended) Use of said adsorbent according to claim 1, for production of adsorbent material for adsorbing high-mobility-group proteins in body fluid.

REMARKS

The specification has been amended to provide a cross-reference to the previously filed International Application.

The claims have been amended to delete some multiple dependencies.

Entry of the above amendments is earnestly solicited. An early and favorable first action on the merits is earnestly solicited.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By G.M. Murphy #36,623
Gerald M. Murphy, Jr., #28,977

GMM/rem
0760-0298P

P.O. Box 747
Falls Church, VA 22040-0747
(703) 205-8000

Attachment: VERSION WITH MARKINGS TO SHOW CHANGES MADE

VERSION WITH MARKINGS TO SHOW CHANGES MADE

The specification has been amended to provide a cross-reference to the previously filed International Application.

IN THE CLAIMS:

The claims have been amended as follows:

18. (Amended) The adsorbent according to [any one of claims 1 to 16] claim 1, wherein said water-insoluble carrier is in the form of beads.

19. (Amended) The adsorbent according to [any one of claims 1 to 18] claim 1, which is used for therapy of sepsis.

20. (Amended) A body fluid-purification column for removing high-mobility-group proteins, comprising a column, and said adsorbent according to [any one of claims 1 to 19] claim 1, which adsorbent is packed in said column.

23. (Amended) A method for adsorbing high-mobility-group proteins in body fluid, comprising contacting said adsorbent according to [any one of claims 1 to 18] claim 1 with body fluid so as to adsorb said high-mobility-group proteins in said body fluid to said adsorbent.

25. (Amended) The method according to [or 24] claim 23,
wherein said body fluid is blood.

28. (Amended) Use of said adsorbent according to [any one of
claims 1 to 18] claim 1, for production of adsorbent material for
adsorbing high-mobility-group proteins in body fluid.

(Rev. 11/13/01)